Healio: Top in Cardiology: Highlights from the American College of Cardiology Scientific Session

Adults with obesity-related heart failure and diabetes saw improvements in heart failure symptoms and physical function with semaglutide 2.4 mg compared with placebo, a recent study showed.

The data were presented at the American College of Cardiology Scientific Session.

“This study offers clear confirmation...of very large benefits on symptoms and physical limitations due to HF with semaglutide vs. placebo,” Mikhail Kosiborod, MD, FACC, FAHA, a cardiologist at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine, told Healio.

Read the full Healio article: Top in Cardiology: Highlights from the American College of Cardiology Scientific Session